Sponsor content
302 result(s) found, displaying 1 to 10
-
Cancellation by sponsorRequested by Abbvie Pty Ltd
-
Abbvie Pty Ltd - OPTIVE Fusion Unit dose - Lubricant, eye Cancelled under Section 41GL(d) of the Act
Cancellation by sponsorRequested by Abbvie Pty Ltd -
Apr-2026Prescription medicine evaluationActive ingredient: upadacitinib hemihydrate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ELAHERE mirvetuximab soravtansine 100 mg/20 mL concentrate solution for intravenous infusion vial.
-
Cancellation by sponsorRequested by Abbvie Pty Ltd
-
Cancellation by sponsorRequested by Abbvie Pty Ltd
-
Cancellation by sponsorRequested by Abbvie Pty Ltd
-
Prescription medicine registrationActive ingredients: glecaprevir, pibrentasvir.
-
Prescription medicine decision summaryElahere (mirvetuximab soravtansine) has been approved to treat adults with folate receptor-alpha (FRα) positive cancer of the ovary, fallopian tubes, or peritoneum who have stopped responding to platinum based chemotherapy and who have had one to 3 chemotherapy treatments before.
-